Translational Results of Zo-NAnTax: A Phase II Trial of Neoadjuvant Zoledronic Acid in HER2-Positive Breast Cancer

Translational Results of Zo-NAnTax: A Phase II Trial of Neoadjuvant Zoledronic Acid in HER2-Positive Breast Cancer

Breast cancer is a heterogeneous disease with distinct clinical and molecular characteristics. Scientific advances in molecular subtype differentiation support the understanding of cellular signaling, crosstalk, proliferation, survival, migration, and invasion mechanisms, allowing the development of...

Full description

Bibliographic Details
Main Authors: Susanne Crocamo, Renata Binato, Everton Cruz dos Santos, Bruno de Paula, Eliana Abdelhay
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:International Journal of Molecular Sciences
Subjects:
breast cancer
HER2-positive
differential expression genes
zoledronic acid
Online Access:https://www.mdpi.com/1422-0067/23/24/15515

Similar Items

Similar Items